Ondine Announces Consolidation of US Operations into New Bothell, WA Facilities

    VANCOUVER, April 18 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) announced today a significant expansion of its US-based facilities,
providing the basis for accelerated product development in both the oral care
and MRSA sectors. Ondine's wholly owned research subsidiary will vacate its
facilities in Redmond and move into new premises located in Bothell,
    Ondine will also close its office in York, Pennsylvania, and sales and
marketing functions will be consolidated to Ondine's corporate head office in
Vancouver, B.C. and the new Bothell, Washington facility. York-based
Jacqueline Walker, Chief Operating Officer, will be leaving the company. Tom
Leonardi, also based in York, will be stepping down as Vice President of Sales
and Marketing of Ondine Biopharma (U.S.A.) Inc., in order to pursue
opportunities outside the company. The Company is grateful for the important
contributions that Jacqueline and Tom have made to Ondine, and wishes them
every success in the future.
    "Consolidation of our operations enables greater efficiency and
effectiveness, essential to meeting upcoming milestones," said Carolyn Cross,
President and CEO of Ondine. "The move to our new facilities allows our
product development teams to work closely together as we continue to evolve
Periowave(TM), our groundbreaking Photodisinfection technology, and develop
the next generation of MRSA anti-infectives, leveraging our recent Canadian
and European approvals."

    About Periowave(TM) and Photodisinfection (PDD)
    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the
disinfection. The Photodisinfection technologies were developed by Professor
Michael Wilson and colleagues at the Eastman Dental Institute, University
College London, and licensed to Ondine by UCL Business PLC, University College
London. Additional information about Periowave(TM) is available at

    About Ondine Biopharma Corporation:
    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA and
an international office in St Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com.

    Forward-Looking Statements:
    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890